Gh Research Plc (GHRS)
$10.5
Live
Insights on Gh Research Plc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 9.4%
Performance
- $10.43$10.98$10.50
0.7%
Downside
Day's Volatility :5.04%
Upside
4.37%
- $5.05$14.64$10.50
51.9%
Downside
52 Weeks Volatility :65.51%
Upside
28.28%
Returns
| Period | Gh Research Plc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 61.05% | 1.7% | 0.0% |
6 Months | 61.75% | 11.3% | 0.0% |
1 Year | 40.25% | 5.4% | 1.3% |
3 Years | -43.32% | 13.9% | -22.1% |
Highlights
Market Capitalization | 587.9M |
Book Value | $4.21 |
Earnings Per Share (EPS) | -0.68 |
Wall Street Target Price | 31.75 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -10.72% |
Return On Equity TTM | -15.18% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -41.2M |
Diluted Eps TTM | -0.68 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.94 |
EPS Estimate Next Year | -1.26 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.2 |
Analyst Recommendation
Buy
90%Buy
9%Hold
0
0%Sell
Based on 11 Wall street analysts offering stock ratings for Gh Research Plc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
- Current
- 1M Ago
- 3M Ago
Buy
10
10
11
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 202.38%
Current $10.50
Target $31.75
Technicals Summary
Sell
Neutral
Buy
Gh Research Plc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Gh Research Plc | 5.02% | 61.75% | 40.25% | -43.32% | -43.32% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Gh Research Plc | NA | NA | NA | -0.94 | -0.15 | -0.11 | NA | 4.21 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Gh Research Plc | Buy | $587.9M | -43.32% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Checkpoint Capital LP
0.56%
Corporate Announcements
Gh Research Plc Earnings
Gh Research Plc’s price-to-earnings ratio stands at None
Read More
Company Information
gh research is a privately-held clinical-stage biopharmaceutical company developing novel therapies for the management of mental illness.
Organization | Gh Research Plc |
Employees | 49 |
CEO | Mr. Florian Schonharting M.Sc. (Econ) |
Industry | Services |
